PHP
Parkman Healthcare Partners Portfolio holdings
AUM
$864M
1-Year Return
33.7%
This Quarter Return
+6.59%
1 Year Return
+33.7%
3 Year Return
+258.24%
5 Year Return
+878.92%
10 Year Return
–
AUM
$864M
AUM Growth
+$21.2M
(+2.5%)
Cap. Flow
+$19.1M
Cap. Flow
% of AUM
2.21%
Top 10 Holdings %
Top 10 Hldgs %
32.42%
Holding
103
New
11
Increased
47
Reduced
28
Closed
15
Top Buys
| 1 |
IQVIA
IQV
|
+$17.3M |
| 2 |
GeneDx Holdings
WGS
|
+$16.2M |
| 3 |
Danaher
DHR
|
+$9.25M |
| 4 |
DexCom
DXCM
|
+$8.34M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
+$7.63M |
Top Sells
| 1 |
Becton Dickinson
BDX
|
+$27.6M |
| 2 |
UnitedHealth
UNH
|
+$26.3M |
| 3 |
Stryker
SYK
|
+$10.8M |
| 4 |
Gilead Sciences
GILD
|
+$9.68M |
| 5 |
Tenet Healthcare
THC
|
+$7.84M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
CVS Health
CVS
$93.8B
| $35.7M | 4.11% |
517,807
+21,071
| +4% | +$1.45M |
|
2
Insulet
PODD
$23.8B
| $33.2M | 3.82% |
105,762
-24,752
| -19% | -$7.78M |
|
3
Boston Scientific
BSX
$156B
| $30.4M | 3.5% |
283,166
+57,176
| +25% | +$6.14M |
|
|
4
Alnylam Pharmaceuticals
ALNY
$61.5B
| $30.1M | 3.46% |
92,338
+23,400
| +34% | +$7.63M |
|
|
5
Tenet Healthcare
THC
$16.9B
| $29.7M | 3.42% |
168,884
-44,534
| -21% | -$7.84M |
|
6
Cooper Companies
COO
$13.5B
| $27.4M | 3.15% |
385,479
+72,829
| +23% | +$5.18M |
|
7
Eli Lilly
LLY
$676B
| $26M | 2.98% |
33,296
-5,895
| -15% | -$4.6M |
|
8
Qiagen
QGEN
$9.98B
| $23.9M | 2.75% |
498,107
+138,463
| +39% | +$6.65M |
|
9
Zimmer Biomet
ZBH
$20.3B
| $21.9M | 2.52% |
240,395
+39,895
| +20% | +$3.64M |
|
|
10
Danaher
DHR
$138B
| $21.7M | 2.5% |
110,090
+46,840
| +74% | +$9.25M |
|
11
Neurocrine Biosciences
NBIX
$14B
| $20.9M | 2.4% |
166,010
-2,372
| -1% | -$298K |
|
|
12
Stryker
SYK
$146B
| $19.9M | 2.29% |
50,376
-27,314
| -35% | -$10.8M |
|
|
13
DexCom
DXCM
$29.8B
| $19.7M | 2.27% |
225,875
+95,508
| +73% | +$8.34M |
|
14
Edwards Lifesciences
EW
$46B
| $19.7M | 2.26% |
251,741
+50,922
| +25% | +$3.98M |
|
|
VRNA
15
Verona Pharma
VRNA
$9.2B
| $18.7M | 2.15% |
197,898
-62,523
| -24% | -$5.91M |
|
16
Viridian Therapeutics
VRDN
$1.62B
| $18.2M | 2.09% |
1,298,825
+234,319
| +22% | +$3.28M |
|
|
17
IQVIA
IQV
$31.3B
| $17.3M | 1.98% |
+109,500
| New | +$17.3M |
|
|
18
GeneDx Holdings
WGS
$3.54B
| $16.2M | 1.86% |
+175,000
| New | +$16.2M |
|
19
Revvity
RVTY
$9.58B
| $15.2M | 1.75% |
157,196
+17,639
| +13% | +$1.71M |
|
|
20
Gilead Sciences
GILD
$143B
| $14.6M | 1.68% |
131,675
-87,275
| -40% | -$9.68M |
|
21
Kiniksa Pharmaceuticals
KNSA
$2.68B
| $13.5M | 1.55% |
488,796
-273,825
| -36% | -$7.58M |
|
22
McKesson
MCK
$87.8B
| $12.8M | 1.47% |
17,458
-4,643
| -21% | -$3.4M |
|
23
BioMarin Pharmaceuticals
BMRN
$10.5B
| $12.4M | 1.42% |
225,150
-52,102
| -19% | -$2.86M |
|
24
Travere Therapeutics
TVTX
$2.43B
| $12.2M | 1.41% |
827,060
-127,011
| -13% | -$1.88M |
|
25
Schrodinger
SDGR
$1.34B
| $11.8M | 1.36% |
587,556
+106,086
| +22% | +$2.13M |
|